What do changes in inflammatory bowel disease management mean for our patients?

Journal of Crohn's and Colitis

Volumn 6, Issue SUPPL.2, 2012, Pages

  Ghosh, Subrata ^a   D'Haens, Geert ^b   Feagan, Brian G ^c   Silverberg, Mark S ^d   Szigethy, Eva M ^e  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Benefit risk; Crohn's disease; Inflammatory bowel disease (IBD); Medical decision making; Motivational communication

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; GLUCOCORTICOID; INFLIXIMAB; MESALAZINE;

ARTICLE; CROHN DISEASE; DISEASE COURSE; DOCTOR PATIENT RELATION; HEALTH CARE PERSONNEL; HOSPITALIZATION; INTERPERSONAL COMMUNICATION; MEDICAL DECISION MAKING; MOTIVATION; PATIENT EDUCATION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; MOTIVATION; PATIENT CARE PLANNING; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859031735     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/S1873-9946(12)60504-2     Document Type: Article

References (36)

1. Colombel J, Rutgeerts P, Sandborn WJ, Camez A, Pollack PF, Chen N, Yang M, Chao J, Mulani PM Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND. J Crohn's Colitis 2010, 4:S11. OP31 at ECCO 2010.
2. Ferrante M, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel J-F, Panaccione R Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. J Crohns Colitis 2012, 6:116-131.
3. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 2010, 59:141-147.
4. Rutgeerts P, et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease - first results of the EXTEND Trial. Gastroenterology 2009, 136:S1. A-116 at DDW 2009.
5. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.
6. Siegel C Making therapeutic decisions in IBD: the role of patients. Curr Opin Gastroenterol 2009, 25:334-338.
7. Siegel CA Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut 2011 Dec 20, [Epub ahead of print]. 10.1136/gutjnl-2011-300988.
8. Siegel CA Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther 2011, 33:23-32.
9. Bauchner H, Simpson L, Chessare J Changing physician behaviour. Arch Dis Child 2001, 84:459-462.
10. Baars JE, Markus T, Kuipers EJ, van der Woude CJ Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion 2010, 81:113-119.
11. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD000296. DOI: 10.1002/14651858.CD000296.pub3.
12. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, Kerr EA The quality of health care delivered to adults in the United States. N Engl J Med 2003, 348:2635-2645.
13. Scott SD, Albrecht L, O'Leary K, Ball GD, Dryden DM, Hartling L, Hofmeyer A, Jones CA, Kovac Burns K, Newton AS, Thompson D, Klassen TP A protocol for a systematic review of knowledge translation strategies in the allied health professions. Implement Sci 2011, 6:58.
14. von Neumann J, Morgenstern O Theory of games and economic behavior 1947, Princeton University Press, Princeton, NJ, (first edition: 1944). 2nd ed.
15. Gregor JC, McDonald JW, Klar N, Wall R, Atkinson K, Lamba B, Feagan B An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997, 3:265-276.
16. Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, Sands BE Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007, 133:769-779.
17. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
18. Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
19. Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009, 15:1308-1319.
20. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P, SONIC Study Group Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
21. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630. Erratum in: Clin Gastroenterol Hepatol 2006; 4:931.
22. Stuck AE, Minder CE, Frey FJ Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963.
23. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010, 105:289-297.
24. Conklin LS, Oliva-Hemker M Nutritional considerations in pediatric inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010, 4:305-317.
25. Humira: EPAR - product information. European Medicines Agency, updated 2012. (Accessed January 27, 2012, at ). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf.
26. Remicade: EPAR - product information. European Medicines Agency, updated 2011. (Accessed January 27, 2012, at ). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf.
27. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
28. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011, 106:2146-2153.
29. IMPACT: 2010-11 Crohn's and ulcerative colitis patient life impact survey. First full results: November 2011. (Accessed January 24, 2012 at ). http://www.efcca-solutions.net/impact/european.php.
30. Cravo M, Guerreiro CS, dos Santos PM, Brito M, Ferreira P, Fidalgo C, Tavares L, Pereira AD Risk factors for metabolic bone disease in Crohn's disease patients. Inflamm Bowel Dis 2010, 16:2117-2124.
31. Miller WR, Rollnick S Ten things that motivational interviewing is not. Behav Cogn Psychoth 2009, 37:129-140.
32. Miller WR, Rollnick S Motivational interviewing: preparing people to change addictive behavior 1991, Guilford Press, New York.
33. Gance-Cleveland B Motivational interviewing: improving patient education. J Pediatr Health Care 2007, 21:81-88.
34. Chen SM, Creedy D, Lin HS, Wollin J Effects of motivational interviewing intervention on self-management, psychological and glycemic outcomes in type 2 diabetes: A randomized controlled trial. Int J Nurs Stud 2011, [Epub ahead of print].
35. Prochaska JO, DiClemente CC Toward a Comprehensive Model of Change. Treating Addictive Behaviors: Processes of Change 1986, 3-27. Plenum Press, New York. W.R. Miller, N. Heather (Eds.).
36. Prochaska JO, Velicer WF The transtheoretical model of health behavior change. Am J Health Promot 1997, 12:38-48.